Comparative Pharmacology
Head-to-head clinical analysis: DALGAN versus NUBAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALGAN versus NUBAIN.
DALGAN vs NUBAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
None Documented
None Documented
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic